Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Schönland

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Zeitschrift Fur Rheumatologie|January 16, 2016
[Causes and treatment of systemic amyloidosis]N Blank, U Hegenbart, S Schönland
Der Internist|October 29, 2011
[Systemic amyloidoses]S Schönland, N Blank, A V Kristen, et al.
Blood Cancer Journal|February 25, 2017
Mutational landscape reflects the biological continuum of plasma cell dyscrasiasA Rossi, M Voigtlaender, S Janjetovic, et al.
Bone Marrow Transplantation|September 15, 2015
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMTT Ruutu, L C de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|November 12, 2014
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent yearsH W Auner, R Szydlo, J Hoek, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Bone Marrow Transplantation|May 28, 2013
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow TransplantationH W Auner, R Szydlo, A van Biezen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Bone Marrow Transplantation|January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trialS Iacobelli, L C de Wreede, S Schönland, et al.
Leukemia|April 28, 2016
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working PartyM Sobh, M Michallet, G Gahrton, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Zeitschrift Fur Rheumatologie|January 16, 2016
[Causes and treatment of systemic amyloidosis]N Blank, U Hegenbart, S Schönland
Der Internist|October 29, 2011
[Systemic amyloidoses]S Schönland, N Blank, A V Kristen, et al.
Blood Cancer Journal|February 25, 2017
Mutational landscape reflects the biological continuum of plasma cell dyscrasiasA Rossi, M Voigtlaender, S Janjetovic, et al.
Bone Marrow Transplantation|September 15, 2015
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMTT Ruutu, L C de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|November 12, 2014
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent yearsH W Auner, R Szydlo, J Hoek, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Bone Marrow Transplantation|May 28, 2013
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow TransplantationH W Auner, R Szydlo, A van Biezen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Bone Marrow Transplantation|January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trialS Iacobelli, L C de Wreede, S Schönland, et al.
Leukemia|April 28, 2016
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working PartyM Sobh, M Michallet, G Gahrton, et al.
Pageof 2